Zealand Pharma A/s Stock
Zealand Pharma A/s Stock
A loss of -1.590% shows a downward development for Zealand Pharma A/s.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Zealand Pharma A/s stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Zealand Pharma A/s in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Zealand Pharma A/s vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zealand Pharma A/s | -1.590% | -6.137% | -5.318% | -38.702% | -32.581% | 139.207% | - |
| Saniona AB | 3.030% | 12.173% | 48.048% | 242.957% | 182.521% | 684.095% | -4.964% |
| Actinium Pharmaceuticals Inc. | 3.820% | 10.561% | 21.597% | 15.717% | 16.421% | -87.152% | -86.256% |
| NanoViricides Inc. | -3.670% | 1.942% | -15.323% | -24.460% | -30.000% | -16.799% | -64.041% |
News
Why Rocket Lab Stock Keeps Going Up
Rocket Lab (NASDAQ: RKLB) stock rocketed to a 10th straight day of gains Friday, surging 5.7% through 11:15 a.m. ET after announcing the New Zealand-based space company announced yet another big
Cantor Boosts Rocket Lab Target to Street-High $35
Aerospace and defense corporation Rocket Lab USA (NASDAQ: RKLB) recently received a significant analyst boost when Cantor Fitzgerald increased its target price for the space company to a
